Sie sind nicht angemeldet! Dieses Tagebuch ist öffentlich einsehbar und wird demnächst zurückgesetzt.
 | |||||||
| |||||||
| © tratabu.de
© tratabu.de
|
Dividendenzahlungen |
|||
| Titel | Ex-Datum | Zahldatum | Bruttobetrag |
Fresenius Medical Care AG & Co. KGaA |
23.05.25 |
27.05.25 |
1.4400 € |
Fresenius Medical Care AG & Co. KGaA |
17.05.24 |
1.1900 € |
|
Fresenius Medical Care AG & Co. KGaA |
19.05.23 |
1.1200 € |
|
Fresenius Medical Care AG & Co. KGaA |
17.05.23 |
1.1200 € |
|
Fresenius Medical Care AG & Co. KGaA |
13.05.22 |
1.3500 € |
|
Fresenius Medical Care AG & Co. KGaA |
21.05.21 |
1.3400 € |
|
Fresenius Medical Care AG & Co. KGaA |
28.08.20 |
1.2000 € |
|
Fresenius Medical Care AG & Co. KGaA |
20.05.20 |
1.2000 € |
|
Fresenius Medical Care AG & Co. KGaA |
17.05.19 |
1.1700 € |
|
Fresenius Medical Care AG & Co. KGaA |
16.05.19 |
1.1700 € |
|
Fresenius Medical Care AG & Co. KGaA |
18.05.18 |
1.0600 € |
|
Fresenius Medical Care AG & Co. KGaA |
12.05.17 |
0.9600 € |
|
Fresenius Medical Care AG & Co. KGaA |
13.05.16 |
0.8000 € |
|
Fresenius Medical Care AG & Co. KGaA |
20.05.15 |
0.7800 € |
|
Fresenius Medical Care AG & Co. KGaA |
16.05.14 |
0.7700 € |
|
Fresenius Medical Care AG & Co. KGaA |
17.05.13 |
0.7500 € |
|
Fresenius Medical Care AG & Co. KGaA |
11.05.12 |
0.6900 € |
|
Fresenius Medical Care AG & Co. KGaA |
13.05.11 |
0.6500 € |
|
Fresenius Medical Care AG & Co. KGaA |
12.05.10 |
0.6100 € |
|
Fresenius Medical Care AG & Co. KGaA |
08.05.09 |
0.5800 € |
|
Fresenius Medical Care AG & Co. KGaA |
21.05.08 |
0.5400 € |
|
Fresenius Medical Care AG & Co. KGaA |
16.05.07 |
0.4700 € |
|
Fresenius Medical Care AG & Co. KGaA |
10.05.06 |
0.4100 € |
|
Fresenius Medical Care AG & Co. KGaA |
13.02.06 |
0.0400 € |
|
Fresenius Medical Care AG & Co. KGaA |
25.05.05 |
0.3733 € |
|
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 07.05.25 16:30:00 | FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y |  |
| Fresenius Medical Care AG & Co. FMS reported first-quarter 2025 adjusted earnings per share (EPS) of 44 cents, which surpassed the Zacks Consensus Estimate by 2.1%. The bottom line improved 22.2% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) FMS’ Revenue Details Revenues of $5.14 billion (EUR 4,881 million) missed the Zacks Consensus Estimate by 2.2%. The company’s reported revenues increased 3.3% year over year and 1.2% at constant currency (cc). Also, revenues were up 5.4% organically. Per management, during the first quarter, divestitures realized as part of the portfolio optimization plan affected revenue development by -260 basis points. Shares of this company gained nearly 3.6% in today’s pre-market trading. The company’s shares have gained 21.1% year to date against the industry’s decline of 10.7%. The S&P 500 Index has decreased 5% in the same period.Zacks Investment Research Image Source: Zacks Investment Research Segmental Details Fresenius Medical implemented a new operating model in 2024 and started reporting under two new segments, Care Delivery and Care Enablement. Care Delivery The segment’s revenues were up 1.8% on a year-over-year basis but down 0.9% at cc. However, revenues gained 4.2% on an organic basis. Revenues in the U.S. markets improved 6.4% reportedly and gained 4.1% on an organic basis. The top line improved 3.2% year over year at cc. Per management,a growing value-based care business, reimbursement rate increases, and a favorable payor mix, as well as exchange rate effects, had a positive impact on the segment’s growth, compensating for a decrease in dialysis days. Per management, during the first quarter of 2025, U.S. same-market treatment growth was flat year over year. International sales declined 19.1% reportedly and 19% at cc but gained 4.8% on an organic basis. The decline was due to divestments realized as part of the portfolio optimization plan and a decrease in dialysis days, which was partially offset by organic growth. The organic growth was supported by accelerated same-market treatment growth of 2.5%. Care Enablement The segment’s revenues increased 5.4% year over year reportedly and 4.9% at cc as well as organically. The growth was driven by volume growth in all the company’s geographical regions and continued positive pricing momentum. Per management, volume-based procurement in China developed in line with expectations, supporting volume growth while acting as a headwind to price development. Margin Analysis In the quarter under review, Fresenius Medical’s gross profit improved 0.9% year over year. However, the gross margin contracted 60 basis points (bps) to 24.3%. Story Continues Selling, general & administrative expenses declined 3.2% on a reported basis. Research and development expenses decreased 9% year over year. Adjusted operating income improved 11.4% from the prior-year quarter. The adjusted operating margin in the first quarter expanded 58 bps to 8%. Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS SurpriseFresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote 2025 Guidance In 2025, Fresenius Medical expects revenue growth to be positive, with a low-single-digit percent rate compared to the prior year. The company also expects operating income to grow by a high-teens to high-twenties percent rate compared to the prior year. Our Take FMS exited the first quarter on a mixed note, with its earnings and revenues surpassing and missing their respective consensus estimate. Overall pricing momentum also supported growth in the Care Enablement segment. However, the effects of elevated mortality will likely continue to have a negative impact on sales. Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 68 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 28 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 750 million by 2025-end. The company’s continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources. FMS’ Zacks Rank & Other Stocks to Consider FMS carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks from the industry that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 07.05.25 07:04:15 | Fresenius Medical Care AG (FMS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... | |
| Organic Revenue Growth: 5% with contributions from both Care Delivery and Care Enablement. Operating Income Growth: 11% increase, consistent with the expected phasing of the full year outlook. Net Leverage Ratio: Improved to 2.8x, below the self-imposed target range. Care Enablement Margin: Improved to 8.3%, entering the target margin band of 8% to 12%. Same Market Treatment Growth (U.S.): Stable, with a 0.5% plus expected growth for 2025. Same Market Treatment Growth (International): Accelerated to 2.5%. Lives Under Management: Increased from around 130,000 to around 148,000 by the end of March. Special Items Impact: Negatively affected group operating income by EUR126 million. Operating Cash Flow: Increased by 28% against last year's quarter due to improved operating working capital. Bond Issuance: Placed 2 bond tranches with an aggregate volume of EUR1.1 billion. Warning! GuruFocus has detected 10 Warning Signs with FMS. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Fresenius Medical Care AG (NYSE:FMS) reported strong organic revenue growth of 5% in Q1 2025, driven by both Care Delivery and Care Enablement segments. The FME25 transformation program delivered EUR68 million in additional sustainable savings, contributing to the company's financial health. Operating income grew by 11%, positioning the company well for future quarters. The net leverage ratio improved to 2.8x, below the self-imposed target range, indicating strong financial discipline. Care Enablement segment achieved a margin of 8.3%, entering its target margin band of 8% to 12% for the first time. Negative Points The severe flu season led to increased missed treatments, impacting same market treatment growth in the U.S. Divestitures negatively impacted revenue development by 260 basis points. Special items, including costs related to portfolio optimization and the FME25 transformation program, negatively affected group operating income by EUR126 million. Labor and inflation costs offset some of the earnings developments in the Care Delivery segment. The company faced a headwind from one less dialysis day in the quarter, affecting absolute volume development and utilization. Q & A Highlights Q: What are you seeing in April trading in the U.S., and how does this impact your confidence in the full-year guidance? A: The flu season hit hard in February and March, but we are encouraged by the underlying referrals, which are a strong leading indicator. We expect the mortality effect to show with a 6- to 8-week lag. We are confident in our positive trajectory and maintaining our 0.5% growth guidance for the year. - Helen Giza, CEO Story Continues Q: Can you provide an update on the revenue per treatment trend in the U.S. and its sustainability? A: We are seeing continued price and mix improvement, supported by the PPS rate increase and moderate price increases across the payer portfolio. This trend is developing in line with our expectations. - Helen Giza, CEO Q: How are you pitching the HDF treatment to competitor clinics, and what are the operational benefits? A: HDF offers significant mortality improvement and operational benefits, such as simpler use, no need for saline, quicker clean downtime, and reduced training time. We are excited about its potential and will provide more details at our Capital Markets Day. - Helen Giza, CEO Q: What is the impact of the current foreign exchange environment on your financials? A: In Q1, we had a positive FX tailwind with an average rate of 1.05. If the euro-U.S. dollar remains at current levels, we expect a 2% to 3% headwind on both top and bottom lines for the full fiscal year 2025. - Martin Fischer, CFO Q: Can you discuss the remaining FME25 savings expected for this year and any potential divestitures? A: We started well with EUR68 million in savings and expect further contributions from Care Enablement and G&A functions. Regarding divestitures, we are mostly done, but will continue to review our portfolio for performance. - Martin Fischer, CFO and Helen Giza, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 06.05.25 09:08:22 | Fresenius: Q1 Earnings Snapshot |  |
| BAD HOMBURG, Germany (AP) — BAD HOMBURG, Germany (AP) — Fresenius Medical Care AG (FMS) on Tuesday reported first-quarter profit of $158.8 million. On a per-share basis, the Bad Homburg, Germany-based company said it had net income of 26 cents. Earnings, adjusted for non-recurring costs, were 44 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 43 cents per share. The dialysis services provider posted revenue of $5.13 billion in the period, which missed Street forecasts. Three analysts surveyed by Zacks expected $5.25 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FMS at https://www.zacks.com/ap/FMS View Comments |
||
| 05.05.25 15:09:00 | Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss? | |
| The first-quarter 2025 earnings season is underway for the Medical sector (one of the 16 broad Zacks sectors within the Zacks Industry classification), with several MedTech companies already releasing their quarterly results. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Per the latest Earnings Preview, the Medical sector is one of the nine sectors whose first-quarter earnings are expected to be above the year-earlier period. It is also one of the sectors that is likely to witness double-digit earnings growth in 2025. This is likely to result from strong product revenues on growing demand across all industries, offsetting the shortcomings caused by worldwide geopolitical issues and policy changes. A stronger U.S. dollar may also have created headwinds for domestic medical device companies by making their products costlier overseas. MedTech companies like Fresenius Medical Care AG FMS, Masimo Corporation MASI and Clover Health Investments, Corp. CLOV are likely to have been positively impacted by these tailwinds despite encountering turbulence on the macroeconomic front. The latest Earnings Preview indicates that 45% of the companies in the Medical sector, constituting nearly 57.9% of the sector’s market capitalization, reported earnings until April 30. Of these, 66.7% beat earnings and revenue estimates. Earnings increased 85.2% year over year on the back of 70.4% higher revenues. Overall, first-quarter 2025 earnings of the Medical sector are expected to improve 40% on the back of an 8.3% sales increase. This compares with fourth-quarter 2024 earnings growth of 13.4% and 9.4% reported revenue growth. Per the latest trends, the Medical sector is one of the nine sectors whose first-quarter 2025 earnings are expected to be above the year-earlier level. MedTech Quarterly Synopsis The continued adoption of generative Artificial Intelligence, or genAI, and digital therapies is helping to provide more efficient and patient-friendly services. Rising innovation and investment in this space are being driven by an aging population, growing healthcare awareness and increasing access to better health options. Many MedTech players are likely to have tapped into the growing demand for patient-centric healthcare solutions, generating new revenue opportunities. Market experts believe these trends will be a major driving force behind the current earnings season. Although the scorecard so far reflects encouraging results, the sector may have faced challenges in the first quarter due to ongoing macroeconomic uncertainties stemming from the geopolitical environment, supply-chain disruptions driving up costs for labor and raw materials, and a shortage of freight and healthcare workers. Changes in U.S. trade policies, tariffs and the reaction of other countries are likely to have weighed heavily on MedTech companies, creating profitability pressures in the first quarter. Story Continues Overall, the January-March months were marked by strength in product portfolios and solid customer adoption of products. Let’s observe the status of the three MedTech players who are scheduled to announce results on May 6. MedTech Stocks to Watch Fresenius Medical Care: Fresenius Medical Care’s first-quarter 2025 revenues are likely to have been aided by the continued execution of the FME25 transformation program, which has already delivered EUR 567 million in cumulative savings, well ahead of schedule. These efficiencies, spanning back-office functions, manufacturing, and supply chain, are helping to cushion the impact of persistent headwinds such as elevated U.S. dialysis patient mortality and portfolio divestitures. However, elevated mortality rates in the U.S. dialysis market have persisted, affecting treatment volumes and overall growth. Additionally, labor cost inflation is expected to result in a net labor headwind of EUR 150 million to EUR 200 million in 2025, primarily due to wage increases. (Read more: Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?) Fresenius Medical Care AG & Co. KGaA Price and EPS SurpriseFresenius Medical Care AG & Co. KGaA Price and EPS Surprise Fresenius Medical Care AG & Co. KGaA price-eps-surprise | Fresenius Medical Care AG & Co. KGaA Quote The Zacks Consensus Estimate for first-quarter 2025 earnings per share (EPS) is pegged at 43 cents. Revenues are expected to be $5.25 billion. Fresenius Medical Care does not have the right combination of the two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) — which increases the odds of an earnings beat. FMS has an Earnings ESP of -9.94% and a Zacks Rank #1. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Masimo: Masimo’s first-quarter 2025 results might have been favored by strength across its major product platforms, with pulse oximetry, CO-Oximetry and hemodynamics, capnography and gas and brain monitoring. During the last reported quarter, the company continued to realize the benefits of manufacturing its high-volume sensors in Malaysia. This is likely to have aided the company in the to-be-reported quarter as well, thereby driving up Masimo’s revenues. Masimo Corporation Price and EPS SurpriseMasimo Corporation Price and EPS Surprise Masimo Corporation price-eps-surprise | Masimo Corporation Quote The Zacks Consensus Estimate for first-quarter EPS is pegged at $1.24. Revenues are expected to be $367.3 million. MASI has an Earnings ESP of 0.00% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here. Clover Health: Clover Health’s first-quarter 2025 revenues are likely to have been driven by sustained strong member retention and cohort management. Per management, the last reported quarter was a pivotal quarter that marked a significant turning point with adjusted EBITDA profitability and strong membership growth. It reported a 27% year-over-year increase in Medicare Advantage membership and a 95% retention rate, which are clear indicators of its competitive benefits and improved star ratings. Despite these positives, challenges include Clover Health’s rapid expansion, which will likely pressure near-term margins, as new members typically have higher loss ratios before cost efficiencies materialize. Clover Health Investments, Corp. Price and EPS SurpriseClover Health Investments, Corp. Price and EPS Surprise Clover Health Investments, Corp. price-eps-surprise | Clover Health Investments, Corp. Quote The Zacks Consensus Estimate for first-quarter loss per share is pegged at 7 cents. Revenues are expected to be $476.9 million. CLOV has an Earnings ESP of 0.00% and a Zacks Rank #3. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Masimo Corporation (MASI) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Clover Health Investments, Corp. (CLOV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 02.05.25 15:05:00 | Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings? | |
| Fresenius Medical Care FMS is scheduled to report first-quarter 2025 results on May 6, after market close. In the last reported quarter, the company’s adjusted earnings per share of 48 cents beat the Zacks Consensus Estimate by 17.1%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Let us look at how things have shaped up for FMS prior to the announcement. Factors That Might Have Driven FMS’ Q1 Performance As Fresenius Medical Care prepares to report its first-quarter 2025 results, several underlying factors from late 2024 are likely to shape its performance trajectory. A major driver is the continued execution of the FME25 transformation program, which has already delivered EUR 567 million in cumulative savings, well ahead of schedule. These efficiencies, spanning back-office functions, manufacturing, and supply chain, are helping to cushion the impact of persistent headwinds such as elevated U.S. dialysis patient mortality and portfolio divestitures. Operationally, the company entered 2025 with positive momentum in U.S. same-market treatment growth, which turned positive in the fourth quarter of 2024 (0.5%), reflecting successful efforts to streamline clinic operations and reduce missed treatments. With weather disruptions largely mitigated and early-year patient trends looking solid, the first quarter is expected to reflect further stabilization, even as management monitors flu season risks and volume recovery dynamics closely. Another area to watch is the Care Enablement segment, which showed a sharp turnaround with a 10% organic revenue increase and a six-fold jump in operating income, driving the margin to 7.8%. This momentum, supported by ongoing price strength and improved operational efficiency, is likely to extend into the first quarter. Meanwhile, while the commercial launch of the FDA-approved 5008X Hemodiafiltration system will ramp more meaningfully in the second half, its strategic significance and clinical potential could begin to feature in management commentary. Investors will also be looking for signs of further progress on FMS’s value-based care strategy and whether the company can sustain its 2024 margin gains as it targets 11%–12% operating income margins for 2025. Overall, the first quarter of 2025 is set to be a key checkpoint in FMS’s final year of its turnaround plan. However, FMS continues to face challenges that may impact its performance in the first quarter of 2025. Elevated mortality rates in the U.S. dialysis market have persisted, affecting treatment volumes and overall growth. Additionally, labor cost inflation is expected to result in a net labor headwind of EUR 150 million to EUR 200 million in 2025, primarily due to wage increases. These factors, combined with the ongoing volatility in the value-based care sector and the implementation of volume-based procurement in China, pose risks to the company's financial performance in the upcoming quarter. Story Continues FMS’ Segmental Overview Fresenius’ Care Delivery segment, which includes its core dialysis services, enters the first quarter of 2025 on a cautiously optimistic note. Despite facing headwinds from persistently elevated U.S. patient mortality and labor shortages, the segment showed stabilization in the fourth quarter of 2024, with U.S. same-market treatment growth turning slightly positive. The company has ramped up efforts to improve staffing and clinical efficiency, while also maintaining a strong focus on cost discipline. With ongoing benefits from the FME25 transformation program and early signs of patient volume recovery, Care Delivery is poised to post moderate sequential growth. However, the segment will continue to be challenged by inflationary labor costs and possible fluctuations in treatment volumes due to flu season and other seasonal mortality effects. The Care Enablement segment—which comprises FMS’s products, including dialysis machines and related services—is expected to show stronger momentum in the first quarter of 2025. The segment is riding on recent wins such as the FDA approval of its new 508x hemodialysis machine, a critical innovation expected to drive product sales and differentiate the company in mature markets. Moreover, the execution of supply chain improvements and progress on manufacturing optimization from the FME25 initiative have helped this segment return to profitability in 2024, and this trajectory is likely to continue. The main risk remains the implementation of volume-based procurement regulations in China, which could pressure pricing and margins. Nonetheless, the higher adoption of new technology and the resilient demand for it in North America and EMEA regions support a positive outlook. Fresenius Medical Care AG & Co. KGaA Price and EPS SurpriseFresenius Medical Care AG & Co. KGaA Price and EPS Surprise Fresenius Medical Care AG & Co. KGaA price-eps-surprise | Fresenius Medical Care AG & Co. KGaA Quote Q1 Estimates The Zacks Consensus Estimate for revenues is pegged at $5.25 billion, implying growth of 2.3% year over year. The Zacks Consensus Estimate for earnings per share is pinned at $0.43, suggesting an improvement of 19.4% from the prior-year level. What the Zacks Model Unveils Our proven model does not conclusively predict an earnings beat for FMS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -9.94%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3 at present. FMS’ Long-Term Growth Potential Fresenius Medical Care is executing a robust transformation under its FME25 program. It is now targeting EUR 750 million in sustainable cost savings by the end of 2025—an upgrade from the previous EUR 650 million goal. As of year-end 2024, the company had already achieved EUR 567 million in savings, driven primarily by a more efficient operating structure, supply chain optimization, and manufacturing enhancements. These initiatives have helped stabilize margins, with Care Delivery reaching more than 10% and Care Enablement jumping to 6.1%, nearly tripling year over year. This strong operational turnaround lays a resilient foundation for long-term margin expansion and profitability, with 2025 expected to deliver high-teens to high-20s percent growth in operating income. Moreover, portfolio optimization, such as divestitures of non-core businesses, including Spectra Labs and exits from several dialysis markets, further streamlines operations and frees up capital for reinvestment into higher-return areas. Innovation is a core growth pillar for FMS, with the upcoming full commercial launch of the FDA-approved 5008X Hemodiafiltration (HDF)-capable dialysis machine in 2026. This next-generation device has already begun initial treatments and is expected to dramatically enhance patient outcomes. HDF, already standard in Europe, is linked to a 23% reduction in all-cause mortality compared to conventional dialysis. The company believes this breakthrough could not only improve care but also boost patient volumes in the United States, helping reverse the recent stagnation caused by elevated mortality and chronic disease burdens. The rollout of the 5008X will form a strategic centerpiece of FMS's Capital Markets Day in June 2025, where further innovations are expected to be unveiled, reinforcing its transition from a dialysis service provider to a technology-enabled care company. FMS also continues expanding its value-based care model through InterWell Health, a joint venture managing over $11 billion in medical costs by 2025. Although the division posted a negative EBIT contribution of EUR 20–40 million in 2024, revenue grew to EUR 1.8 billion, and management expects breakeven performance in 2025. This model aligns financial incentives with patient outcomes and is central to the company’s long-term strategy of holistic kidney care, spanning early-stage CKD, dialysis, transplantation, and home-based therapies. The strategic shift toward managing total patient care rather than just treatments positions FMS for more sustainable, scalable growth as healthcare systems worldwide prioritize cost efficiency and quality outcomes. Our Take on FMS FMS’s shares have gained 10.5% in the year-to-date period against the industry’s decline of 9.1%. The broader S&P 500 Index declined 5.8% in the same time frame. The company’s challenges may lead to mixed performance going forward. Per the Zacks Style Score, a proprietary method for evaluating stocks, the company looks moderately valued (Value Score: B) with a moderate chance of continued uptrend (Growth Score: C). However, the pace is likely to be sluggish (Momentum Score: F). As the Zacks Rank, coupled with the style score for FMS, does not conclusively predict that the company may beat on earnings this reporting cycle, we caution against any new investment bet in FMS at present. Those who have already invested in the stock may sell a portion of their investments and book profits.Zacks Investment Research Image Source: Zacks Investment Research Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: ANI PharmaceuticalsANIP has an Earnings ESP of +0.86% and a Zacks Rank #1. The company is slated to release first-quarter 2025 results on May 9. You can see the complete list of today’s Zacks #1 Rank stocks here. ANIP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.32%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 30.6% from the year-ago quarter figure. CencoraCOR has an Earnings ESP of +0.82% and a Zacks Rank #2. The company is slated to release first-quarter fiscal 2025 results on May 7. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 4.94%. The Zacks Consensus Estimate for COR’s fiscal first-quarter EPS is expected to rise 7.1% from the year-ago reported figure. Hims & Hers Health HIMS has an Earnings ESP of +34.35% and a Zacks Rank #2. The company is slated to release first-quarter 2025 results on May 5. HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 40.42%. The Zacks Consensus Estimate for Hims & Hers Health’s first-quarter EPS is expected to increase 180% from the year-ago quarter figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 23.04.25 13:40:15 | Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock? | |
| While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits. On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. One stock to keep an eye on is Fresenius Medical Care AG & Co. (FMS). FMS is currently holding a Zacks Rank of #1 (Strong Buy) and a Value grade of A. The stock has a Forward P/E ratio of 10.87. This compares to its industry's average Forward P/E of 26.28. Over the last 12 months, FMS's Forward P/E has been as high as 14.62 and as low as 10.46, with a median of 11.79. We also note that FMS holds a PEG ratio of 0.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. FMS's PEG compares to its industry's average PEG of 2.10. FMS's PEG has been as high as 1.15 and as low as 0.71, with a median of 0.91, all within the past year. Finally, we should also recognize that FMS has a P/CF ratio of 5.55. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 19.99. Within the past 12 months, FMS's P/CF has been as high as 6.06 and as low as 4.28, with a median of 5.02. Value investors will likely look at more than just these metrics, but the above data helps show that Fresenius Medical Care AG & Co. Is likely undervalued currently. And when considering the strength of its earnings outlook, FMS sticks out at as one of the market's strongest value stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Story Continues This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 17.04.25 12:50:00 | Why Fresenius Medical Care Stock Might be a Great Pick | |
| One stock that might be an intriguing choice for investors right now is Fresenius Medical Care AG FMS. This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Instruments space as it currently has a Zacks Industry Rank of 66 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there. Meanwhile, Fresenius Medical Care is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term. Fresenius Medical Care AG Price and ConsensusFresenius Medical Care AG & Co. KGaA Price and Consensus Fresenius Medical Care AG price-consensus-chart | Fresenius Medical Care AG Quote In fact, over the past month, current quarter estimates have risen from 44 cents per share to 45 cents per share, while current year estimates have risen from $2.01 per share to $2.11 per share. This has helped FMS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here. So, if you are looking for a decent pick in a strong industry, consider Fresenius Medical Care. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 16.04.25 13:07:00 | Volatile Markets? Try These Relative Price Strength Stocks | |
| April has been a rough ride for the stock market, shaken by broad U.S. tariffs and escalating global trade tensions. With tariffs climbing as high as 145% on imports from major partners like China—and China responding with 84% duties on U.S. products—investors are understandably nervous. Ongoing inflation pressures and worries about a possible recession or stagflation are adding to the uncertainty. As a result, the S&P 500 has slipped into correction territory, down more than 8% for the year. Investors looking to stay ahead in this environment may want to consider the power of relative price strength. Even during volatile stretches, certain stocks continue to outperform their peers. This strategy—focusing on names that hold up better than the broader market—can help investors stay aligned with underlying momentum. In a choppy market like today’s, that relative strength can be a key to navigating the turbulence and capturing long-term gains. At this stage, investors would be wise to consider stocks like IHS Holding Limited IHS, Atlanticus Holdings Corporation ATLC, REX American Resources Corporation REX and Fresenius Medical Care AG FMS based on their relative price strength. Relative Price Strength Strategy Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. However, these are also essential for determining whether a stock’s price performance is better than its peers or the industry average. If a stock’s performance is lacking that of the broader groups, despite impressive earnings growth or valuation multiples, then something must be wrong. It’s always advisable to stay away from these stocks and bet on those that are outperforming their respective industry or benchmark. This is because betting on a winner always proves to be lucrative. Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals indicate room for growth and are the best ways to go about this strategy. Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains. Story Continues Screening Parameters Relative % Price change – 12 weeks greater than 0 Relative % Price change – 4 weeks greater than 0 Relative % Price change – 1 week greater than 0 (We have considered those stocks that have been outperforming the S&P 500 over the last 12 weeks, four weeks and one week.) % Change (Q1) Est. over 4 Weeks greater than 0: Positive current-quarter estimate revisions over the last four weeks. Zacks Rank equal to 1: Only Zacks Rank #1 (Strong Buy) stocks — that have returned more than 26% annually over the last 26 years and surpassed the S&P 500 in 23 of the last 26 years — can get through. You can see the complete list of today’s Zacks #1 Rank stocks here. Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000: A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity. VGM Score less than or equal to B: Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential. Here are the four stocks that made it through the screen: IHS Holding Limited: Based in London, it is one of the largest independent owners, operators, and developers of shared telecommunications infrastructure globally. The Zacks Consensus Estimate for 2025 earnings of IHS Holding indicates 114.7% growth. The company has a VGM Score of A. Over the past 60 days, the Zacks Consensus Estimate for IHS Holdings 2025 earnings has moved up 30.9%. The company has a market capitalization of $1.6 billion. IHS shares have gone up 62.7% in a year. Atlanticus Holdings: Headquartered in Atlanta, GA, this is a fintech company offering credit cards, auto loans, and banking solutions, leveraging data and tech to serve U.S. consumers through its CaaS and Auto Finance segments. The Zacks Consensus Estimate for 2025 earnings for ATLC indicates 29.4% growth. It has a VGM Score of B. Atlanticus Holdings beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 11.4%, on average. Atlanticus Holdings shares have jumped 110.5% in a year. REX American Resources: Based in Dayton, OH, REX American Resources is a Midwest-based ethanol producer with stakes in six plants. It focuses on high-efficiency output and growth, including potential carbon capture initiatives. The company’s current market capitalization is $676.4 million. REX American Resources has a VGM Score of B. Notably, over the past 60 days, the Zacks Consensus Estimate for REX American Resources’ fiscal 2026 earnings has moved up 15.7%. It beat the Zacks Consensus Estimate for earnings in each of the last four quarters, with the average being 92.8%. REX shares have gone down 31.3% in a year. Fresenius Medical Care AG: Based in Bad Homburg, Germany, it is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. The Zacks Consensus Estimate for 2025 earnings of Fresenius Medical Care indicates 27.1% growth. It has a VGM Score of A. Fresenius Medical Care beat the Zacks Consensus Estimate for earnings in three of the last four quarters and met in the other. It has a trailing four-quarter earnings surprise of roughly 15.7%, on average. FMS shares have risen 31.8% in a year. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report IHS Holding Limited (IHS) : Free Stock Analysis Report REX American Resources Corporation (REX) : Free Stock Analysis Report Atlanticus Holdings Corporation (ATLC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 16.04.25 10:30:00 | Zacks.com featured highlights include Alibaba, Fresenius Medical, Helix Energy Solutions and Heritage Insurance | |
| For Immediate Release Chicago, IL – April 16, 2025 – Stocks in this week’s article are — like Alibaba Group BABA, Fresenius Medical Care AG FMS, Helix Energy Solutions Group Inc. HLX and Heritage Insurance Holdings, Inc. HRTG. 4 Top-Ranked High-Earnings-Yield Value Stocks to Buy Right Away President Trump’s announcement of reciprocal tariffs, followed by a 90-day pause, caused major swings in the U.S. stock market. The S&P 500 dropped 9% in the first week of April, marking its worst week since 2020. It then rebounded 5.7% the next week, the best since 2023. A major one-day gain came last Wednesday after Trump paused most tariffs, which boosted investor confidence. Yesterday, markets were lifted by exemptions from reciprocal tariffs on items like smartphones, semiconductors and solar cells. This led to a strong tech rally and extended last week’s gains. However, the S&P 500 remained below its level from April 2, before the tariffs were announced. Uncertainty around a potential global trade war still worries investors and economists. In such volatile times, value investing stands out as a smart, stable strategy for long-term gains. Alibaba Group, Fresenius Medical Care AG, Helix Energy Solutions Group Inc. and Heritage Insurance Holdings, Inc. are a few solid high-value picks with high earnings yields. Power Up Your Portfolio Value With Earnings Yield Metric Value investing means buying stocks that are priced below what they are really worth. It works on the idea that markets often misprice stocks, giving investors a chance to buy low and profit later. One simple tool value investors use is earnings yield. It shows how much profit a company makes for each dollar of its stock price. Earnings yield, expressed in percentage, is calculated as (Annual Earnings per Share/Market Price) x 100. It is the reverse of the price-to-earnings (P/E) ratio. A high earnings yield may mean the stock is undervalued. A low yield could mean the stock is too expensive. Investors can also use earnings yield to compare stocks with bond returns like the 10-year Treasury yield. If the stock market's earnings yield is higher than the bond yield, stocks might be more attractive. With regard to this, earnings yield can be more illuminating than the traditional P/E ratio, as the former facilitates the comparison of stocks with fixed-income securities. Our Picks Here we discuss four of the 42 stocks that qualified the screening: Alibaba: The company has cemented its position as the undisputed e-commerce powerhouse in China and is rapidly expanding its international presence. Alibaba operates through seven segments — China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. Story Continues The Zacks Consensus Estimate for BABA’s fiscal 2025 and 2026 earnings implies year-over-year growth of 2.1% and 23%, respectively. EPS estimates for the current and next fiscal year have moved up by 8 cents and 59 cents, respectively, over the past 60 days. Alibaba currently sports a Zacks Rank #1 and has a Value Score of B. Fresenius Medical: It is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Fresenius Medical recently launched the newest version of its home dialysis machine, NxStage Versi HD with GuideMe Software. The Zacks Consensus Estimate for FMS’ 2025 and 2026 earnings implies year-over-year growth of 27.1% and 9.1%, respectively. EPS estimates for the current and next year have moved up by 10 cents and 9 cents, respectively, over the past 30 days. Fresenius Medical currently sports a Zacks Rank #1 and has a Value Score of A. HelixEnergy: It is an international offshore energy company. Helix Energy provides specialty services to the offshore energy industry, with a focus on their growing well intervention and robotics operations. The Zacks Consensus Estimate for HLX’s 2025 and 2026 earnings implies year-over-year growth of 42% and 28.2%, respectively. EPS estimates for the current and next year have moved up by 12 cents and 14 cents, respectively, over the past 60 days. Helix Energy currently sports a Zacks Rank #1 and has a Value Score of A. Heritage Insurance: It provides personal and commercial residential insurance products. Heritage Insurance’s focus on rate adequacy, selective underwriting and profit-oriented underwriting criteria while restricting new business in over-concentrated markets or products poises it well for growth. The Zacks Consensus Estimate for HRTG’s 2025 and 2026 earnings implies year-over-year growth of 21% and 28.6%, respectively. EPS estimates for the current and next year have moved up by 64 cents and 73 cents, respectively, over the past 60 days. Heritage Insurance currently sports a Zacks Rank #1 and has a Value Score of A. You can get the rest of the stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2449125/4-top-ranked-high-earnings-yield-value-stocks-to-buy-right-away Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Zacks.com Phone: 312-265-9268 Email: pr@zacks.com Visit: https://www.zacks.com/ Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Helix Energy Solutions Group, Inc. (HLX) : Free Stock Analysis Report Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report Heritage Insurance Holdings, Inc. (HRTG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 15.04.25 13:45:00 | 4 Top-Ranked High Earnings Yield Value Stocks to Buy Right Away | |
| President Trump’s announcement of reciprocal tariffs, followed by a 90-day pause, caused major swings in the U.S. stock market. The S&P 500 dropped 9% in the first week of April, marking its worst week since 2020. It then rebounded 5.7% the next week, the best since 2023. A major one-day gain came last Wednesday after Trump paused most tariffs, which boosted investor confidence. Yesterday, markets were lifted by exemptions from reciprocal tariffs on items like smartphones, semiconductors and solar cells. This led to a strong tech rally and extended last week’s gains. However, the S&P 500 remained below its level from April 2, before the tariffs were announced. Uncertainty around a potential global trade war still worries investors and economists. In such volatile times, value investing stands out as a smart, stable strategy for long-term gains. Alibaba Group BABA, Fresenius Medical Care AG FMS, Helix Energy Solutions Group Inc. HLX and Heritage Insurance Holdings, Inc. HRTG are a few solid high-value picks with high earnings yields. Power Up Your Portfolio Value With Earnings Yield Metric Value investing means buying stocks that are priced below what they are really worth. It works on the idea that markets often misprice stocks, giving investors a chance to buy low and profit later. One simple tool value investors use is earnings yield. It shows how much profit a company makes for each dollar of its stock price. Earnings yield, expressed in percentage, is calculated as (Annual Earnings per Share/Market Price) x 100. It is the reverse of the price-to-earnings (P/E) ratio. A high earnings yield may mean the stock is undervalued. A low yield could mean the stock is too expensive. Investors can also use earnings yield to compare stocks with bond returns like the 10-year Treasury yield. If the stock market's earnings yield is higher than the bond yield, stocks might be more attractive. With regard to this, earnings yield can be more illuminating than the traditional P/E ratio, as the former facilitates the comparison of stocks with fixed-income securities. The Winning Strategy We have set an Earnings Yield greater than 10% as our primary screening criterion but it alone cannot be used for picking stocks that have the potential to generate solid returns. So, we have added the following parameters to the screen: Estimated EPS growth for the next 12 months greater than or equal to the S&P 500: This metric compares the 12-month forward EPS estimate with the 12-month actual EPS. Story Continues Average Daily Volume (20 Day) greater than or equal to 100,000: High trading volume implies that a stock has adequate liquidity. Current Price greater than or equal to $5. Buy-Rated Stocks: Stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have been known to outperform peers in any type of market environment. You can see the complete list of today’s Zacks #1 Rank stocks here. Our Picks Here we discuss four of the 42 stocks that qualified the screening: Alibaba: The company has cemented its position as the undisputed e-commerce powerhouse in China and is rapidly expanding its international presence. Alibaba operates through seven segments — China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. The Zacks Consensus Estimate for BABA’s fiscal 2025 and 2026 earnings implies year-over-year growth of 2.1% and 23%, respectively. EPS estimates for the current and next fiscal year have moved up by 8 cents and 59 cents, respectively, over the past 60 days. Alibaba currently sports a Zacks Rank #1 and has a Value Score of B. Fresenius Medical: It is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Fresenius Medical recently launched the newest version of its home dialysis machine, NxStage Versi HD with GuideMe Software. The Zacks Consensus Estimate for FMS’ 2025 and 2026 earnings implies year-over-year growth of 27.1% and 9.1%, respectively. EPS estimates for the current and next year have moved up by 10 cents and 9 cents, respectively, over the past 30 days. Fresenius Medical currently sports a Zacks Rank #1 and has a Value Score of A. HelixEnergy: It is an international offshore energy company. Helix Energy provides specialty services to the offshore energy industry, with a focus on their growing well intervention and robotics operations. The Zacks Consensus Estimate for HLX’s 2025 and 2026 earnings implies year-over-year growth of 42% and 28.2%, respectively. EPS estimates for the current and next year have moved up by 12 cents and 14 cents, respectively, over the past 60 days. Helix Energy currently sports a Zacks Rank #1 and has a Value Score of A. Heritage Insurance: It provides personal and commercial residential insurance products. Heritage Insurance’s focus on rate adequacy, selective underwriting and profit-oriented underwriting criteria while restricting new business in over-concentrated markets or products poises it well for growth. The Zacks Consensus Estimate for HRTG’s 2025 and 2026 earnings implies year-over-year growth of 21% and 28.6%, respectively. EPS estimates for the current and next year have moved up by 64 cents and 73 cents, respectively, over the past 60 days. Heritage Insurance currently sports a Zacks Rank #1 and has a Value Score of A. You can get the rest of the stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Helix Energy Solutions Group, Inc. (HLX) : Free Stock Analysis Report Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report Heritage Insurance Holdings, Inc. (HRTG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
